Healthcare

Healthcare Insights

실적, 시장 구조, 재무제표에 대한 리서치 노트입니다. 각 글은 결론부터 시작하고, 이후 근거와 시사점을 정리합니다.

2026-07-21

Cardinal Health Buys AdaptHealth Diabetes Unit + Strive Medical for $360M Cash — Home-Care Roll-Up Continues insight cover

2026년 7월 21일

CAH•7분 읽기

Cardinal Health Buys AdaptHealth Diabetes Unit + Strive Medical for $360M Cash — Home-Care Roll-Up Continues

On July 20, 2026, Cardinal Health announced definitive agreements to acquire AdaptHealth's Diabetes Health business (~$235M cash) and Strive Medical — a DME supplier serving 20,000+ patients — for a combined ~$360M in cash. The deals expand Cardinal Health's Cardinal at-Home Solutions segment, deepening its position in diabetes supplies and durable medical equipment. AdaptHealth framed the divestiture as sharpening focus on its core sleep, respiratory, and HME businesses.

Total purchase price: $360MAdaptHealth diabetes business value: $235M

3M’s Q2 2026 Setup: A Small EPS/Revenue Miss Is Less Concerning Than the Tariff-Cost Test to Its Back-Half Organic Growth insight cover

2026년 7월 21일

MMM•8분 읽기

3M’s Q2 2026 Setup: A Small EPS/Revenue Miss Is Less Concerning Than the Tariff-Cost Test to Its Back-Half Organic Growth

3M (3M Company) delivered Q2 2026 results that were slightly below consensus on both adjusted EPS and revenue, while reiterating full-year guidance for ~3% organic sales growth. The market focus is whether the post-Solventum footprint can keep the organic-sales pace as tariff drag hits consumer-leaning SKUs and pricing/mix. With recent quarterly revenue running in a narrow band (~$6.0B–$6.5B), the “execution” question is not demand collapse—it’s margin bridge durability.

Adjusted EPS (Q2 2026): $2.24Revenue (Q2 2026): $6.4B

Scribe Therapeutics’ $100M IPO Is the First Public “Pure-Play CRISPR Risk Read” of 2H 2026—And It’s Valuing Epigenetic Gene Editing Like a Clinical-Stage Bet insight cover

2026년 7월 21일

SCTX•9분 읽기

Scribe Therapeutics’ $100M IPO Is the First Public “Pure-Play CRISPR Risk Read” of 2H 2026—And It’s Valuing Epigenetic Gene Editing Like a Clinical-Stage Bet

Scribe Therapeutics (Scribe Therapeutics) set Nasdaq IPO terms for 7.15M shares at $13–$15, seeking about $100M at the low end and up to $107.2M at the top, with Sanofi participating in a concurrent purchase. The S-1 frames its core value creation around early, in-human data for its lead epigenetic CRISPR program (Scribe Therapeutics STX-1150]) and preclinical progress for two lipid-risk follow-ons funded partly by CIRM grants. For investors, the key question isn’t just CRISPR’s science—it’s whether public markets will underwrite early-stage execution risk after the post-2024/25 biotech window reopened.

Offer size (shares): 7.15MPrice range: $13.00–$15.00

2026-07-20

Samsung Biologics $1.8B All-Cash Bid for PolyPeptide: Korea's Biggest CDMO Bet Yet on the GLP-1 Peptide Boom insight cover

2026년 7월 20일

207940.KS•11분 읽기

Samsung Biologics $1.8B All-Cash Bid for PolyPeptide: Korea's Biggest CDMO Bet Yet on the GLP-1 Peptide Boom

On July 19-20, 2026, Samsung Biologics launched an all-cash public tender offer to acquire 100% of Swiss API peptide manufacturer PolyPeptide Group at CHF 44.31 per share, valuing the deal at approximately CHF 1.46 billion (~$1.8B) and marking the largest overseas acquisition by a Korean CDMO. The offer carries a 40% premium to the undisturbed April 10 price and an 11.6% premium to the 60-day VWAP, and is backed by an irrevocable tender undertaking from PolyPeptide's largest shareholder representing ~55.65% of shares. Strategically, the deal gives Samsung Biologics a multi-modality platform with six GMP facilities across Europe, the US and India and direct exposure to GLP-1 peptide manufacturing, competing with Novo Holdings' $16.5B Catalent acquisition and CordenPharma's ~$1B peptide CDMO push.

Offer price (cash): CHF 44.31Equity value: ~CHF 1.46B

2026-07-19

Taylor Farms recall dashboard showing Cyclospora risk, lettuce sourcing from central Mexico, and retail distribution footprint

Consumer / Food Safety

2026년 7월 19일

XLP•11분 읽기

Taylor Farms' Cyclospora Recall Shows How One Lettuce Channel Can Spread Across Taco Bell and 27 States

Taylor Farms' July 17 recall turns a central Mexico lettuce sourcing channel into a network-risk case for retailers and quick-service restaurants. The public-health signal came from shredded iceberg lettuce served at Taco Bell, but the commercial unwind spans a 27-state distribution footprint and multiple packed formats.

Recall announcement date: 2026-07-17Outbreak scope: 1,644+

2026-07-18

Meta data-center racks, AWS cloud routing, AI capex, and a business-model shift dashboard

AI / Cloud Infrastructure

2026년 7월 18일

META•12분 읽기

Meta's AWS Poach Turns AI Infrastructure Into a Cloud-Business Trial

Hiring a senior Amazon Web Services executive is a small headline with a large read-through: Meta is no longer just buying compute, it is starting to organize itself like a compute platform. That changes the valuation debate around AI capex, cloud economics, and what counts as a durable moat.

2026 capex guide: $125B-$145BPotential Anthropic deal: $10B

Skyroot Vikram-1 launch, India's private space market, and orbital access economics

Industrials / Space

2026년 7월 18일

SPCX•11분 읽기

Skyroot's Vikram-1 Launch Opens India's Private Orbital Market to the Rest of the Space Stack

India's first private orbital launch is a milestone, but the market implication is bigger: launch access is becoming a commercial market, which matters for Rocket Lab, SpaceX, defense contractors, and every satellite company trying to buy time in orbit.

Payloads: 6Delay: 35 min

Skyroot Vikram-1 launch, Indian space sector growth, and a commercial launch market dashboard

Industrials / Space

2026년 7월 18일

SPCX•11분 읽기

Skyroot's First Private Orbital Rocket Turns India Into a New Launch-Provider Market

The Vikram-1 launch is more than a national milestone. It shows that India has crossed from a government-led space program into a private launch market, which matters for launch pricing, satellite deployment, and the long-term economics of commercial space.

Mission: AagamanPayloads: 6

SpaceX Starship on the pad, engine abort telemetry, and a valuation chart for launch reliability

Industrials / Space

2026년 7월 18일

SPCX•11분 읽기

SpaceX Scrubbed Starship Flight 13, and Launch Reliability Is Now the Real Valuation Test

The abort of Starship Flight 13 matters because the market is no longer valuing SpaceX only on ambition. It is valuing the company on whether the launch system can become reliable enough to support Starlink, NASA, and a much larger future launch cadence.

Engines that failed to ignite: 4Flight number: 13

2026-07-17

Healthcare dashboard with medical-cost ratio, earnings beat, and Dow support for UnitedHealth

Healthcare / Managed Care

2026년 7월 17일

UNH•10분 읽기

UnitedHealth's Guidance Raise Turns the Dow's Defensive Engine Back On

UnitedHealth's strong quarter matters because it showed that medical-cost control can still drive both earnings and index support. In a week when tech was weak, that is exactly the kind of defensive ballast the Dow needs.

Adjusted EPS: $6.38Revenue: $112.0B

2026-07-16

A healthcare margin dashboard with claims, pricing curves, and a rising earnings line for UnitedHealth

Healthcare / Earnings

2026년 7월 16일

UNH•13분 읽기

UnitedHealth's 86.7% Medical-Cost Ratio Turned a Healthcare Beat Into a Margin-Discipline Trade

UnitedHealth reported second-quarter 2026 adjusted earnings per share of $6.38 on $112.0 billion of revenue, lowered its medical-cost ratio to 86.7%, and raised full-year adjusted EPS guidance to $19.50-$20.00. The market reaction was immediate, but the real signal is that management is now prioritizing pricing discipline, mix, and cost control over top-line optics. That changes the read-through for managed care peers and for the healthcare sector's place in the July 16 tape.

Adjusted EPS: $6.38Revenue: $112.0B

2026-07-14

An Alzheimer's patient using an at-home autoinjector while a distant infusion clinic and brain amyloid imaging fade into the background

Healthcare / Neuroscience

2026년 7월 14일

BIIB•14분 읽기

Biogen and Eisai Just Removed the Infusion Chair From the Start of the Alzheimer's Treatment Journey

The FDA's July 14 approval of LEQEMBI IQLIK as a subcutaneous initiation dose gives early-Alzheimer's patients an at-home path from treatment start through maintenance. The strategic consequence is larger than convenience: Biogen and Eisai can now attack the infusion-capacity, travel, staffing, and scheduling friction that limited the commercial reach of anti-amyloid therapy, while safety monitoring and diagnosis remain the true bottlenecks.

FDA action: Jul. 14Initiation dose: 500 mg

2026-07-13

Medicare Advantage recovery graphic with shield, claims flow, and margin repair signals

Healthcare / Earnings

2026년 7월 13일

UNH•10분 읽기

UnitedHealth and Elevance Health Are the Next Test of the Medicare Advantage Recovery

The next two insurer calls will tell the market whether the 2026 MA payment reset and easing utilization are enough to extend the rally in UnitedHealth, Elevance Health, and peers, or whether medical-cost inflation is starting to creep back.

MA payment update: +5.06%Elevance call: Jul 15

2026-07-11

Healthcare AI assistant, longitudinal care, and patient management graphic

AI / Healthcare

2026년 7월 11일

GOOGL•9분 읽기

Google's AMIE Turns Healthcare AI Into Disease-Management Infrastructure

Google says AMIE can reason through longitudinal disease management as well as, and in some respects better than, clinicians in a new Nature study. The market implication is that healthcare AI is moving beyond one-off diagnosis into workflow infrastructure for follow-up, triage, and plan quality, which matters for Alphabet, virtual-care vendors, and payer care-management stacks.

Clinicians compared: 21Study venue: Nature

2026-07-10

Drug supply chain registry, manufacturing nodes, and FDA visibility graphic

Healthcare / Manufacturing

2026년 7월 10일

LLY•10분 읽기

FDA's Drug-Manufacturing Registry Rule Tightens the Supply-Chain Map

The FDA proposed a rule that would let distributed manufacturers register as a single establishment, require advance notice before unit relocation, and close visibility gaps for foreign establishments that make active pharmaceutical ingredients and other drugs for U.S.-linked supply chains. The market implication is that supply-chain transparency is becoming a policy requirement, which favors manufacturers that can prove traceability and domestic resilience, including Eli Lilly and other scaled pharma operators.

Rule type: ProposedRegistration model: Single establishment

2026-07-09

Biotech trial and molecule graphic showing late-stage readout risk

Healthcare / Pharma

2026년 7월 9일

AZN / IONS•7분 읽기

AstraZeneca's Wainua Trial Miss Shows Late-Stage Biotech Risk Still Reprices Fast

AstraZeneca's Phase III CARDIO-TTRansform readout failed its primary objective, and the market immediately repriced the downside. The message is blunt: even quality pharma names can lose billions when one late-stage trial misses.

Primary endpoint: MissedAstraZeneca move: -8%

2026-07-01

Pediatric gene therapy, CRISPR editing, and biotech approval graphic

Healthcare / Biotech

2026년 7월 1일

VRTX / CRSP•9분 읽기

FDA's Casgevy Expansion Pushes Gene Therapy Down the Age Curve

The FDA expanded Casgevy to patients aged 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first gene therapy approved for children that young with SCD. The approval also arrived 53 days after filing, which signals that expedited review can materially compress the risk discount for Vertex and CRISPR Therapeutics.

New age floor: 2 yearsReview speed: 53 days

2026-06-27

Healthcare market graphic with rising capital flow, shield, and pipeline symbols

2026년 6월 27일

XLV•8분 읽기

Healthcare Haven

Healthcare is getting bid as investors rotate out of overheated tech and into cash-rich, pipeline-rich names. AbbVie, Eli Lilly, and Johnson & Johnson all closed at all-time highs, and the market is rewarding balance-sheet discipline, label expansion, and smarter capital allocation instead of pure momentum.

AbbVie week: +14%Lilly week: ATH

2026-06-08

AI compute, sovereign infrastructure, and university research graphic

Semiconductors / AI

2026년 6월 8일

AMD•10분 읽기

AMD's £2 Billion UK AI Push Turns Compute Into Industrial Policy

AMD says it will invest up to £2 billion over five years in the United Kingdom, pairing sovereign AI infrastructure with university partnerships and photonic networking research. The market implication is bigger than one country: compute is becoming a geopolitical asset, and the companies that can sell the full stack get more leverage than the ones selling chips alone.

Investment: £2bnResearch partners: 2+

기대할 수 있는 것

보이는 관점이 있는, 증거 우선의 노트.

이 섹션은 실적, 주주총회, 시장 구조에 대한 날카로운 해석을 모아둡니다. 새 글은 첫 화면 안에서 논지, 사실, 시사점이 모두 드러나야 합니다.

일반론이 아닌 직접적인 분석을 기대하세요.

데이터는 명확하고, 논리는 따라가기 쉬워야 합니다.

About Us•Privacy Policy•Terms of Service•Join our Slack

© Plutux Technology Limited 2026